Immuno-oncology--silver bullets or mass destruction weapons?
Modes of treatment affecting the regulatory mechanisms of cell-mediated immunity are changing the treatment practices of various types of cancer. Antibodies inhibiting regulatory molecules of the immune response, i.e. checkpoint inhibitors, are of particular interest. The mechanism of action is enhancement of the body's intrinsic responses to cancer cells through inhibition of negative regulation of the immune defense. Cell-mediated immunity directed to cancerous tissue can be enhanced by removing the brake associated with T-cell activation (CTLA-4 inhibitors). A more physiological mode of action is to abolish the attenuation mechanism of already activated T cells (PD-1 inhibitors). The physiological purpose of both mechanisms is to prevent an excessively strong immune reaction and thus autoimmunity.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 132(2016), 8 vom: 21., Seite 721-8 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
Immuno-onkologia--hopealuoteja vai joukkotuhoaseita? |
|---|
| Beteiligte Personen: |
Utriainen, Meri [VerfasserIn] |
|---|
| Themen: |
CTLA-4 Antigen |
|---|
| Anmerkungen: |
Date Completed 28.06.2016 Date Revised 01.06.2016 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM260913308 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM260913308 | ||
| 003 | DE-627 | ||
| 005 | 20231224194421.0 | ||
| 007 | tu | ||
| 008 | 231224s2016 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0869.xml |
| 035 | |a (DE-627)NLM260913308 | ||
| 035 | |a (NLM)27244931 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 100 | 1 | |a Utriainen, Meri |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immuno-oncology--silver bullets or mass destruction weapons? |
| 246 | 3 | 3 | |a Immuno-onkologia--hopealuoteja vai joukkotuhoaseita? |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2016 | ||
| 500 | |a Date Revised 01.06.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Modes of treatment affecting the regulatory mechanisms of cell-mediated immunity are changing the treatment practices of various types of cancer. Antibodies inhibiting regulatory molecules of the immune response, i.e. checkpoint inhibitors, are of particular interest. The mechanism of action is enhancement of the body's intrinsic responses to cancer cells through inhibition of negative regulation of the immune defense. Cell-mediated immunity directed to cancerous tissue can be enhanced by removing the brake associated with T-cell activation (CTLA-4 inhibitors). A more physiological mode of action is to abolish the attenuation mechanism of already activated T cells (PD-1 inhibitors). The physiological purpose of both mechanisms is to prevent an excessively strong immune reaction and thus autoimmunity | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Rämet, Mika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 132(2016), 8 vom: 21., Seite 721-8 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2016 |g number:8 |g day:21 |g pages:721-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2016 |e 8 |b 21 |h 721-8 | ||